regulatory
confidence high
sentiment positive
materiality 0.60
FDA reclassifies NRx ketamine ANDA amendment from Major to Minor; goal date Nov 10, 2026
NRX Pharmaceuticals, Inc.
- FDA Office of Generic Drugs reclassified NRx's preservative-free ketamine ANDA amendment from Major to Minor.
- GDUFA goal date revised to November 10, 2026; FDA cites amendment won't require substantial resource expenditure.
- CEO Jonathan Javitt praised FDA speed in advancing approval of this strategic drug-shortage product.
- Reclassification follows written FDA communication received September 15, 2026.